GW Pharmaceuticals Receives Orphan Drug Designation from the European Medicines Agency (EMA) | CashCropToday
0 Shares 312 Views

GW Pharmaceuticals Receives Orphan Drug Designation from the European Medicines Agency (EMA)

February 27, 2018
312 Views

On February 27, 2018, GW Pharmaceuticals, PLC (Nasdaq:GWPH) (“GW) announced that the European Medicines Agency (EMA) has granted orphan drug designation for cannabidiol (CBD) for the treatment of tuberous sclerosis (TS).

GW has started a Phase 3 clinical trial of Epidiolex® (cannabidiol) as an adjunctive therapy for the treatment of seizures associated with TS, with data expected in the second half of 2018.  Subject to positive results, GW will submit regulatory applications in 2019 for Epidiolex in TS in both the U.S. and Europe.

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.

The EMA orphan designation is a status assigned to a medicine intended for use against a rare, chronically debilitating, condition and allows a pharmaceutical company to benefit from incentives offered by the EU.  These incentives can include reduced fees and protection from competition once the medicine is placed on the market. At the time of designation, tuberous sclerosis affected approximately 52,000 people in the European Union.

Tuberous sclerosis, also called tuberous sclerosis complex (TSC), is a rare, multi-system genetic disease that causes benign tumors to grow in the brain and on other vital organs such as the kidneys, heart, eyes, lungs, and skin. It usually affects the central nervous system and results in a combination of symptoms including seizures, developmental delay, behavioral problems, skin abnormalities, and kidney disease.

You may be interested

Aurora Cannabis Provides Investors Updates on their International Operations
Market Watch
9 views
Market Watch
9 views

Aurora Cannabis Provides Investors Updates on their International Operations

Editor - August 13, 2018

Aurora Cannabis (TSX: ACB) (OTCQB: ACBFF) announced this morning a company update on their multiple cannabis related operations around the world. The company has undertaken projects in numerous…

Australians Overwhelmingly Support Medical Cannabis
Global
32 views
Global
32 views

Australians Overwhelmingly Support Medical Cannabis

Editor - August 13, 2018

Ninety one percent of Australians support medicinal cannabis use. Chronic diseases like epilepsy, chronic pain, nausea in cancer related chemotherapy, multiple sclerosis, PTSD, and palliative care are…

Health Canada Issues Significant Changes to Industrial Hemp Regulations
Politics
227 views
Politics
227 views

Health Canada Issues Significant Changes to Industrial Hemp Regulations

Editor - August 11, 2018

Health Canada, the overseeing body in charge of industrial hemp licensing and its regulations has just issued a new class exemption for cultivators of the plant within…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: